All articles tagged with #myelin repair
Scientists have discovered two compounds, K102 and K110, that promote remyelination and could potentially reverse nerve damage caused by multiple sclerosis, with K102 showing particular promise for clinical development.
Researchers have discovered a new biological mechanism for myelin repair and regeneration, focusing on the Daam2 protein and CK2α kinase. Myelin, crucial for efficient neurotransmission, is often damaged in neurological diseases such as multiple sclerosis and cerebral palsy. The study found that phosphorylation of Daam2 by CK2α negatively regulates Wnt activity during white matter development and injury. This discovery offers potential therapeutic pathways for myelin regeneration and provides hope for treating currently untreatable neurological conditions.
Estriol, a hormone produced during pregnancy, has been found to reduce disease severity and promote myelin repair in the cortex, a key brain region affected in multiple sclerosis (MS), in a mouse model of the disease. The hormone has been in use for decades as a therapy to help manage symptoms of menopause and has a generally good safety profile. Based on these promising results, the scientists are calling for studies to examine the potential for this hormone as a treatment for women with MS.
Researchers have found evidence of myelin repair induced by clemastine based on MRI data from the ReBUILD trial, but it can only be partially effective at the doses currently being used and can have a sedative effect. A retrospective opinion piece discusses the challenges that remain in treating MS despite the gains made in recent decades. The PIPE-791 study, a potential treatment aimed at protecting damaged myelin, has been cleared for a Phase 1 study in healthy volunteers.
A new study has identified the over-the-counter antihistamine, clemastine, as an effective drug for brain repair in Multiple Sclerosis (MS) patients. Using a newly-developed MRI scan technique, scientists were able to observe and measure the impact of clemastine on brain myelin levels. The study offers the first documented example of brain repair for a chronic neurological condition through MRI and is expected to set a standard for future research into myelin-rebuilding therapies. Clemastine is also being considered for use in treating brain injury in premature infants, who often experience myelin damage.
A recent study found that yoga is better than physical therapy at improving the quality of life for MS patients. A high-dose vitamin D supplement did not reduce the risk of relapses in people with relapsing-remitting MS (RRMS) already using a disease-modifying therapy. An investigational oral therapy called PIPE-307 is expected to launch a Phase 2 trial to boost remyelination. A new wearable system called NeurOpTrek powered by Sensoria is designed to reduce the risk of falls and improve balance, gait, and coordination for older patients and people with MS.